meta
|
evidence
oncology
Living systematic review and meta-analysis
muscular invasive bladder cancer (MIBC)
MIBC - (neo)adjuvant (NA)
MIBC - NA - all population
2
MIBC - NA - PDL1 positive
1
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
nivolumab based treatment
nivolumab alone
versus all
vs non active control
vs no additional treatment
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
atezolizumab based treatment
nivolumab based treatment
atezolizumab alone
nivolumab alone
MIBC - NA - all population
2
Comparator:
vs no additional treatment;
vs placebo;
Risk of bias:
low;
some concerns;
high;
NA;